Hi It's a marathon of clinical trials to get a new medicine approved and its worth it if MindBio's lead candidate MB22001 can prove more effective and without the side effects seen commonly in anti-depressant medications.READ MORETo date, the trial o...

Hi I am pleased to report that MindBio Therapeutics has completed the acquisition of Life AI Corp, a life sciences focused technology company that is developing predictive technologies for enhancing health and wellness. It's most progressive technolo...

Hi I am delighted to share a novel discovery in our clinical trials. Our engineers have developed a method to determine if a patient has dosed their medicine, simply by analysing their voice!The discovery has led to the announcement today of the acq...

MindBio Therapeutics Corp. Reports Six Month Sustained Antidepressant Response in Clinical Trials. 72% reduction in Depression Severity Recorded.Dear ,We are excited to share significant progress in our mission to transform mental health treatments....

Hi We are thrilled to share some significant progress from our ongoing Phase 2B clinical trial focused on advanced-stage cancer patients experiencing symptoms of anxiety, depression and existential distress. In this Phase 2B study, 40 participants ar...

Hi MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.Photo: Justin Hanka, MindBio CEO and Co-Founder insp...

Hi MindBio is pleased to report on long term stability data for its lead candidate drug MB22001. These stability findings, are an important part of our commercialisation journey, to produce medicines that can be stored and used safely for long perio...

Hi Join me as I discuss MindBio's landmark take-home microdosing clinical trial in patients with Major Depressive Disorder as we enter our 25th participant into this randomized, triple blind, double dummy, active placebo controlled trial.Click to Wat...

Hi I'm pleased to present a brief video update on whats happening at MindBio.We recently reported a sustained anti-depressant response from microdosing MB220001 at 1 months and 3 months post cessation of an 8-week treatment cycle. Our women's health...

Hi We continue take-home dosing in two Phase 2B clinical trials with a third Phase 2B women's health trial recently approved for use of a microdose of a psychedelic medicine (MB22001) to treat mood symptoms in Premenstrual Syndrome and Premenstrual D...